Simple Hospital Feedback Boosts Genetic Screening for Chronic Lung Disease
Genetics

Simple Hospital Feedback Boosts Genetic Screening for Chronic Lung Disease

A multi-hospital study reveals that data-driven clinical audits increased initial blood testing for a common genetic disorder, but confirmatory genetic workups lagged.

By Faisal Qureshi
Published:
Email this Article
Simple Hospital Feedback Boosts Genetic Screening for Chronic Lung Disease
Photo by Robina Weermeijer on Unsplash

A simple review of hospital records across nine public centers in Spain reveals that a structured feedback intervention raised alpha-1 antitrypsin testing in chronic obstructive pulmonary disease patients from 61.1 percent to 71.3 percent, though confirmatory genetic testing for those with deficient levels remained stubbornly low. The study, published in PLOS One, highlights persistent hurdles in closing the gap between respiratory guidelines and daily medical practice.

How Hospital Audits Changed Screening Rates for Chronic Lung Disease

Alpha-1 antitrypsin deficiency is a widespread genetic condition where the body fails to produce enough of a protective liver protein, leaving lung tissue vulnerable to early damage. Despite international medical guidelines urging universal screening for everyone diagnosed with chronic obstructive pulmonary disease, up to 90 percent of affected people remain undiagnosed or mislabeled. To test whether a simple institutional nudge could fix this, researchers conducted a multicenter observational study across Western Andalusia between May and December 2025.

The investigation involved 895 patient records divided across two cross-sectional clinical audits. The first audit evaluated usual care across 452 patients, while the second re-audit reviewed 443 records after participating pulmonologists attended an online educational feedback session. During this session, investigators reviewed baseline performance and discussed recommended diagnostic pathways.

What the Results Reveal About Initial Testing Versus Genetic Confirmation

Following the feedback intervention, serum alpha-1 antitrypsin measurements increased by an absolute 10.3 percentage points, reaching 71.33 percent in the second audit. Statistical analysis pointed to specialized clinics as a major hub for testing, where follow-up care strongly correlated with whether patients received an initial blood draw. Conversely, older age and higher body mass index were independently associated with lower odds of being tested, suggesting clinicians might harbor lower suspicion for the condition in these groups.

However, the second step of the diagnostic pathway did not see the same improvement. For patients with blood levels falling below the critical threshold of 116 milligrams per deciliter, genetic testing rates moved only slightly from 44 percent to 50 percent, a change that was not statistically significant. Out of 36 patients recommended for genetic analysis across both phases, actual testing was completed in a fraction, revealing system-level barriers such as complex referral routes or restricted access to molecular testing.

Understanding the Limitations of Real-World Observational Data

The authors noted several important caveats when interpreting these findings. Because the investigation used an uncontrolled before-and-after design without a separate control group, the changes cannot be definitively proved to stem solely from the feedback sessions. Furthermore, the small number of patients displaying low blood protein levels limited the statistical power available to detect subtle drivers of genetic testing uptake.

Another finding involved inflammatory markers. Because the protein in question acts as an acute-phase reactant during inflammation, measuring it alongside C-reactive protein is recommended to avoid skewed results. Yet simultaneous C-reactive protein checks were absent in several cases where genetic testing was performed despite normal protein concentrations. The team emphasizes that while simple quality-improvement audits can successfully boost initial blood screening, healthcare systems will need more targeted organizational support to ensure patients complete the full diagnostic journey.

The research was published in PLOS One on November 16, 2026.

Fact Checked

This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.

Last reviewed on .

Article history

  • Latest version

Reference(s)

  1. Muñoz-Sánchez, Belén., et al. “Impact of a clinical audit and feedback strategy on the diagnosis of alpha-1 antitrypsin deficiency: A multicenter before-and-after clinical audit study.” PLOS One, vol. 21, no. 11, November 16, 2026, pp. e0362750 Public Library of Science (PLoS), doi: 10.1371/journal.pone.0362750. <https://doi.org/10.1371/journal.pone.0362750>.

Cite this page:

Qureshi, Faisal. “Simple Hospital Feedback Boosts Genetic Screening for Chronic Lung Disease.” BioScience. BioScience ISSN 2521-5760, 16 November 2026. <https://www.bioscience.com.pk/en/subject/genetics/impact-of-a-clinical-audit-and-feedback-strategy-on-the-diagnosis-of-alpha-1-antitrypsin-deficiency-a-multicenter-before-and-after-clinical-audit-study>. Qureshi, F. (2026, November 16). “Simple Hospital Feedback Boosts Genetic Screening for Chronic Lung Disease.” BioScience. ISSN 2521-5760. Retrieved November 16, 2026 from https://www.bioscience.com.pk/en/subject/genetics/impact-of-a-clinical-audit-and-feedback-strategy-on-the-diagnosis-of-alpha-1-antitrypsin-deficiency-a-multicenter-before-and-after-clinical-audit-study Qureshi, Faisal. “Simple Hospital Feedback Boosts Genetic Screening for Chronic Lung Disease.” BioScience. ISSN 2521-5760. https://www.bioscience.com.pk/en/subject/genetics/impact-of-a-clinical-audit-and-feedback-strategy-on-the-diagnosis-of-alpha-1-antitrypsin-deficiency-a-multicenter-before-and-after-clinical-audit-study (accessed November 16, 2026).
End of the article